Stock OMER OMEROS CORPORATION
Add to a list
To use this feature you must be a member
Log inSign up

Press Releases Omeros Corporation

Equities

OMER

US6821431029

Market Closed - Nasdaq
Other stock markets
 16:00:00 2024-06-18 EDT 		5-day change 1st Jan Change
4.09 USD +1.24% Intraday chart for Omeros Corporation +8.49% +25.08%
06-12 Omeros Corporation Announces Executive Changes CI
06-03 Omeros Corporation announced that it expects to receive $92.1 million in funding CI

Press Releases

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Omeros Announces Webcast Details for Annual Meeting of Shareholders
BU
Omeros Corporation Further Strengthens its Balance Sheet through Series of Financing Transactions Extending Maturity on a Majority of its Outstanding Debt into 2028
BU
Omeros: Q1 Earnings Snapshot
AQ
Omeros Corporation Reports First Quarter 2024 Financial Results
BU
OMEROS CORPORATION TO ANNOUNCE FIRST QUARTER FINANCIAL RESULTS ON MAY 15, 2024
AQ
OMEROS CORPORATION ANNOUNCES UPCOMING PRESENTATIONS AT 2024 EUROPEAN HEMATOLOGY ASSOCIATION HYBRID CONGRESS
AQ
Omeros Corporation to Announce First Quarter Financial Results on May 15, 2024
BU
Omeros Corporation Announces Upcoming Presentations at 2024 European Hematology Association (EHA) Hybrid Congress
BU
Omeros: Q4 Earnings Snapshot
AQ
Omeros Corporation Reports Fourth Quarter and Year-End 2023 Financial Results
BU
Omeros Corporation to Announce Fourth Quarter and Year-End Financial Results on April 1, 2024
BU
Omeros Corporation Announces Upcoming Presentation Detailing Narsoplimab Compassionate Use in Nine Patients with Hematopoietic Stem Cell Transplant-associated Thrombotic Microangiopathy
BU
Omeros Corporation Announces Additional Royalty Monetization with DRI Healthcare Trust
BU
Omeros: Q3 Earnings Snapshot
AQ
Omeros Corporation Reports Third Quarter 2023 Financial Results
BU
Omeros Corporation to Announce Third Quarter Financial Results on November 9, 2023
BU
Omeros Announces Online Publication in Advance of ASH Annual Meeting Detailing Narsoplimab Treatment Under Compassionate Use of 15 Patients with Hematopoietic Stem Cell Transplant-associated Thrombotic Microangiopathy
BU
Omeros Corporation Announces Upcoming Presentations at ASH Annual Meeting
BU
Omeros Corporation Hires Andreas Grauer M.D. as Chief Medical Officer
BU
Omeros Corporation Provides Update on Interim Analysis of ARTEMIS-IGAN Phase 3 Trial of Narsoplimab in IgA Nephropathy
BU
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. OMER Stock
  4. News Omeros Corporation
  5. Press Releases